- 专利标题： Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
-
申请号： US16494962申请日： 2018-03-03
-
公开(公告)号： US11879014B2公开(公告)日： 2024-01-23
- 发明人: Anne Goubier , Josephine Salimu , Kevin Moulder , Beatriz Goyenechea Corzo , Pascal Merchiers , Sergio Quezada , Karl Peggs , Frederick Arce Vargas , Isabelle Solomon
- 申请人： Tusk Therapeutics Ltd. , Cancer Research Technology Limited
- 申请人地址： GB Hertfordshire
- 专利权人： Tusk Therapeutics Ltd.,Cancer Research Technology Limited
- 当前专利权人： Tusk Therapeutics Ltd.,Cancer Research Technology Limited
- 当前专利权人地址： GB Hertfordshire; GB London
- 代理机构： Choate, Hall & Stewart LLP
- 代理商 Brenda Herschbach Jarrell; Michael L. Vetter
- 优先权： EP 161717 2017.03.17 GB 10879 2017.07.06 GB 14429 2017.09.07
- 国际申请： PCT/EP2018/056312 2018.03.03
- 国际公布： WO2018/167104A 2018.09.20
- 进入国家日期： 2019-09-17
- 主分类号： C07K16/28
- IPC分类号： C07K16/28 ; A61K39/00 ; C07K14/55 ; A61K45/06
摘要：
The present disclosure relates to use of an anti-CD25 antibody, not inhibiting IL-2-CD25 interaction, with enhanced binding to activating Fc gamma Rs that lead to effective depletion of tumor-infiltrating Treg cells and improved control of established tumors. Combination with anti-programmed cell death protein-1 antibodies further improves tumor rejection.
公开/授权文献
- US20200010554A1 FC-OPTIMIZED ANTI-CD25 FOR TUMOR SPECIFIC CELL DEPLETION 公开/授权日：2020-01-09
信息查询
